The medical technology company Monivent reports lower revenue in the fourth quarter compared with the same period the year before. The operating loss decreased. The board proposes no dividend. Net sales were SEK 0.4 million (0.7).Operating result was -SEK 1.9 million (-3.0). Result after tax was -SEK 1.9 million (-3.1). No ordinary dividend is proposed (0). Cash flow from operating activities amounted to -SEK 1.7 million (-2.1). Cash and cash equivalents amounted to SEK 0.4 million (1.0).In September, the company took out a bridge loan that was disbursed in two tranches, of which the second part was disbursed in January 2026. The capital from the bridge loan takes the company past Q1 2026. The board and management at Monivent are now working together with a financial advisor to best address the company's long-term capital needs. The company further states."After a year of intensive work on ongoing regulatory processes and the adjustment of the commercial strategy, the company is closer to an upcoming launch together with Dräger and to a future geographic expansion."Monivent, SEK mQ4-2025Q4-2024Net sales0.40.7Operating result-1.9-3.0Net result-1.9-3.1Cash flow from operating activities-1.7-2.1Cash and cash equivalents0.41.0Ordinary annual dividend per share, SEK00